![](/wp-content/uploads/2020/06/companionmedical-brightinsight-announcement.png)
$599
Companion Medical’s InPen Approved in Peds; BrightInsight Secures $40M Series B Funding
Two diabetes-related items have been observed: Companion Medical announced FDA approval of its InPen for use in all ages and BrightInsight announced a Series B funding round of $40M. Below, FENIX provides thoughts on the expanded indication for InPen and BrightInsight’s funding.